ERBB3 and breast cancer: The combination of these two miRNAs inhibited HER3 expression and reduced the levels of phosphorylated HER3, AKT, and SRC and, as a consequence, the therapeutic efficacy of TRA and PTX against HER2 + BC was enhanced [137].